1. Search Result
Search Result
Results for "

FGF2

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

25

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-102071

    5'-O-Tritylinosine; 5'-O-Trityl-inosine

    Nucleoside Antimetabolite/Analog Cancer
    KIN59 (5’-O-Tritylinosine) is a potent thymidine phosphorylase allosteric inhibitor. KIN59 inhibits FGF2-stimulated cell growth. KIN59 inhibits the expression of p-FGFR1, P-Akt in FGF2 (10 ng/mL) stimulated cells. KIN59 shows anti-tumor activity .
    KIN59
  • HY-107194

    FGFR Cancer
    NSC 12 is an extracellular trap of fibroblast growth factor 2 (FGF2) that binds FGF2 and interferes with its interaction with FGFR1. NSC12 inhibits the proliferation of different FGF-dependent tumour cells both in vitro and in vivo with no systemic toxic effects .
    NSC12
  • HY-P5133

    SSTN92-119

    Integrin Cancer
    Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 [2].
    Synstatin (92-119)
  • HY-107753

    Ras Inflammation/Immunology Cancer
    XRP44X inhibits Ras-induced transcription activation with the IC50 of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2 . XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules [2].
    XRP44X
  • HY-RS04896

    Small Interfering RNA (siRNA) Others

    FGF2 Human Pre-designed siRNA Set A contains three designed siRNAs for FGF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FGF2 Human Pre-designed siRNA Set A
    FGF2 Human Pre-designed siRNA Set A
  • HY-124827

    Tyrosinase Cancer
    Tec-IN-1 (Compound 21) is a Tec inhibitor (IC50s of 11.7 μM). Tec-IN-1 inhibits Tec-mediated tyrosine phosphorylation of FGF2, and inhibits FGF2 secretion from cells .
    Tec-IN-1
  • HY-123541

    FGFR Tyrosinase Cancer
    Tec-IN-6 (compound 6) is a FGF2 binding to Tec kinase inhibitor, with an IC50 of 8.9 μM (His-FGF2/GST-NΔ173 Tec) .
    Tec-IN-6
  • HY-161841

    FGFR Cancer
    Antitumor agent-177 (compound 57), a non-steroidal NSC12 derivative, shows potent FGF2 binding affinity with a Kd of 24 μM by SPR. Antitumor agent-177 significantly inhibits the formation of HSPG/FGF2/FGFR1 ternary complexes. Antitumor agent-177 inhibits FGFR activation and exerts a potent anti-tumor activity on multiple myeloma (MM) cell lines in vitro and in vivo .
    Antitumor agent-177
  • HY-P990597

    FGFR Inflammation/Immunology
    HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
    HuGAL-F2
  • HY-123453

    NSC 37204

    FGFR Cancer
    SM27 (NSC 37204) is an inhibitor for fibroblast growth factors (FGF). SM27 inhibits angiogenesis through block of FGF2/HSPGs/FGFR1 complex formation .
    SM27
  • HY-161840

    FGFR Cancer
    Antitumor agent-176 (Compound 22), an antitumor agent, can effectively bind to FGF2 and inhibit the activation of fibroblast growth factor receptor (FGFR) in multiple myeloma (MM) cells, exhibiting significant antitumor activity both in vivo and in vitro against MM .
    Antitumor agent-176
  • HY-118184

    PGE synthase Cancer
    AF3485 is a human mPGES-1 inhibitor that exhibits antitumor activity in vitro and in vivo. AF3485 inhibits tumor-associated angiogenesis by reducing PGE2 production, inhibiting EGFR signaling, and decreasing VEGF and FGF-2 expression. AF3485 reduced tumor growth in mice bearing human A431 xenograft tumors by subchronic administration.
    AF3485
  • HY-122704

    Aminoquinuride

    FGFR HSV VEGFR Infection
    Surfen is a potent HS (heparan sulfate) antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins. Surfen affects sulfation of heparin and inhibits degradation by heparin lyases. Surfen inhibits FGF2 binding and signaling. Surfen inhibits cell attachment, and virus infection .
    Surfen
  • HY-122704A
    Surfen dihydrochloride
    1 Publications Verification

    Aminoquinuride dihydrochloride

    FGFR HSV VEGFR Infection
    Surfen dihydrochloride is a potent HS (heparan sulfate) antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins. Surfen affects sulfation of heparin and inhibits degradation by heparin lyases. Surfen inhibits FGF2 binding and signaling. Surfen inhibits cell attachment, and virus infection .
    Surfen dihydrochloride
  • HY-118792

    Endogenous Metabolite Cancer
    AHR activator 1 is an aryl hydrocarbon receptor activator with activity regulating fibroblast growth factor-2 (FGF2)-induced branching morphogenesis. AHR activator 1 prevents the formation of cellular branches by inhibiting AHR signaling. AHR activator 1 also associates with adhesion of dissociated linkers, suggesting the importance of dissociated linkers in the inhibition of branching by AHR agonists. Studies of AHR activator 1 reveal its functional role in mammary gland morphogenesis and play a role in inhibiting FGF-induced invasion .
    AHR activator 1
  • HY-P10870

    Peptide-Drug Conjugates (PDCs) FGFR Apoptosis Cancer
    Pep1-DNP conjugate 9 is a functionalized peptide which is composed of the DNP-Hapten and the FGFR1 binding peptide. Pep1-DNP conjugate 9 exhibits good affinity to FGFR1 with KD of 5.01 μM. Pep1-DNP conjugate 9 recruits anti-DNP antibodies to the surface of FGFR1-positive cells, inhibits the FGF2-induced proliferation in rat skeletal myoblast cells, and induces apoptosis. Pep1-DNP conjugate 9 exhibits antitumor efficacy in mouse models .
    Pep1-DNP conjugate 9
  • HY-P10301

    CXCR Cancer
    CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity .
    CXCL9(74-103)
  • HY-138257A

    AS1069562; (R)-YM-08054 benzenesulfonate

    5-HT Receptor Serotonin Transporter Neurological Disease Metabolic Disease
    (R)-Indeloxazine benzenesulfonate (AS1069562) is an orally active 5-HT and NE reuptake inhibitor, with IC50 values of 0.35 μM and 3.3 μM, respectively. (R)-Indeloxazine benzenesulfonate (AS1069562) possesses curative-like analgesic effect. (R)-Indeloxazine benzenesulfonate (AS1069562) might improve nerve function impairment via the amelioration of neurotrophic support [2].
    (R)-Indeloxazine benzenesulfonate
  • HY-116030

    Integrin Metabolic Disease
    JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization .
    JNJ-26076713

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: